Clinical Trial Detail

NCT ID NCT02649387
Title Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.